MedTrace Logo

A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers

NCT00999817 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2010-01-07

No results posted yet for this study

Summary

A study to study the potential effect of PF-00299804 inhibition of CYP2D6 on dextromethorphan.

Conditions

  • Healthy Volunteers

Interventions

DRUG

reference [dextromethorphan]

single 30 mg oral dose

DRUG

test [PF-00299804 + dextromethorphan]

single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00999817 on ClinicalTrials.gov